CONTEXT: Further evidence of ancestry-based disparities in cancer treatment from this study, believed to be the largest of it’s type so far. The analysis of data from over 11,000 men Continue Reading
CONTEXT: Report of one poster presentation and four abstracts derived from Synapse’ RWD capabilities at ASCO 2021. Further evidence of RWD becoming an increasingly valuable tool for oncology research. IMPACT: Continue Reading
CONTEXT: Commercial announcement from Biodesix and Datavant to enhance their current lung cancer specific RWD biobank. It is hoped that the enhanced datasets will help pin future NSCLC treatments. IMPACT: Continue Reading
CONTEXT: Report of two abstracts presented by Lucence at ASCO 2021 detailing their molecular profiling of advanced cancers in a real-world setting using a liquid biopsy assay and results of Continue Reading
CONTEXT: A philanthropy-fuelled database created at the University of Calgary is proving its value and attracting international attention, including for some highly encouraging new research for treating lung cancer (NSCLC) | Cananda only data Continue Reading
CONTEXT: Report of a paper published in Immunotherapy, May 26th 2021 edition describing RWE study of PD-L1 testing patterns and treatment distribution in patients with NSCLC in Israel. The results Continue Reading
CONTEXT: Commercial announcement of a joint initiative between Hoffmann-La Roche and BC Cancer along with Canadian Personalised Healthcare Innovation Network (CPHIN) to create an RWE framework in British Columbia to Continue Reading
CONTEXT: Publication of abstracts through ASCO on patient derived RWE on two very interesting areas of oncology. The first abstract looks at the reasons behind the low levels of trial Continue Reading
CONTEXT: Roche going big on data at this years ASCO. Multiple RWE studies presented across their oncology portfolio. IMPACT: Medium READ TIME: 2 mins Quality Level Mean [1 – 10]: Continue Reading
CONTEXT: Publication of a retrospective chart review on the effectiveness of Halaven (eribulin mesylate) in metastatic breast cancer | One of the limitations of this study is that detailed safety Continue Reading
